MDWD · CIK 0001593984
What MediWound Ltd. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for MDWD. More may follow as additional filings are processed.
In its own words
What could break it.
Geographic concentration
- single manufacturing site — Yavne, Israelhigh
All near-term revenue depends on products from one manufacturing site in Yavne, Israel (the expanded NexoBrid facility); a shutdown or force majeure — in a country at war — would halt all production with limited inventory cover.
“We currently rely on a single manufacturing site in Yavne, Israel, and we expect that all of our revenues in the near future will be derived from products manufactured at this site.”
Supplier concentration
- bromelain SP — single supplier (CBC) with facilities in Taiwanmedium
The key starting material for every product (NexoBrid, EscharEx, pipeline) comes from one supplier, Challenge Bioproducts Corporation, whose proprietary manufacturing sits in Taiwan — a sole-source dependence stacked on Taiwan geopolitical risk.
“We currently procure bromelain SP, a key substance starting material in the manufacturing of NexoBrid, EscharEx and our pipeline product candidates, from a single supplier, Challenge Bioproducts Corporation Ltd. ("CBC").”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“After the Initial Term and optional two-year extension, Vericel, at its sole discretion, may choose to extend the Supply Agreement's term for additional one-year period for a potential total term of fifteen years.”
Cited →“we entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America.”
Cited →
Its suppliers
Challenge Bioproducts Corporation Ltd. (CBC, Taiwan)
“We currently procure bromelain SP, a key substance starting material in the manufacturing of NexoBrid, EscharEx and our pipeline product candidates, from a single supplier, Challenge Bioproducts Corporation Ltd. ("CBC").”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch